Selected Grants
Biomarkers to distinguish between Type 1 and 2 SLE activity
ResearchPrincipal Investigator · Awarded by Exagen , Inc. · 2020 - 2027IIS-The Relationship between Levels of Antinuclear Antibodies and Other Biomarkers in the Evaluation of Disease Activity in SLE
Clinical TrialPrincipal Investigator · Awarded by Immunovant · 2022 - 2026Improving Quality of Life in SLE by Stratified Personalized Health Planning
ResearchCo Investigator · Awarded by Department of Defense · 2022 - 2026A prosepective Observational registry of patients treated with LUPKYNIS (voclosporin) in the US
Clinical TrialPrincipal Investigator · Awarded by Aurinia Pharmaceuticals, Inc · 2023 - 2025Development and preliminary validation of a patient-reported measure of systemic lupus erythematosus disease activity
ResearchCo Investigator · Awarded by University of California - San Francisco · 2022 - 2025UCB SL0043 A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severly active systemic lupus erythematosus
Clinical TrialCo Investigator · Awarded by UCB Biopharma · 2021 - 2024Mechanisms of Pain in Systemic Lupus Erythematosus
ResearchCo-Principal Investigator · Awarded by Lupus Research Alliance · 2023 - 2024Lysosome Defects and the Accumulation of Immune Complexes in Human Lupus - R01 Sub
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2019 - 2024Prospective observational cohort of patients with moderate-to-severe SLE to characterize cross-sectional and longitudinal disease activity, treatment patterns and effectiveness, outcomes and comorbidities, healthcare resource utilization
ResearchPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2018 - 2023Janssen STELARA Lotus
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2018 - 2022A novel approach to measuring and managing chronic pain, fatigue, and depression in systemic lupus erythematosus.
Clinical TrialCo Investigator · Awarded by Pfizer, Inc. · 2019 - 2022The Health-Related Quality of Life, Fatigue and Health Utility of Patients with Lupus Nephritis
ResearchPrincipal Investigator · Awarded by GlaxoSmithKline · 2021 - 2022A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2018 - 2019Phase I MAD Study of JNJ-55920839
Clinical TrialPrincipal Investigator · Awarded by Janssen Pharmaceutica, Inc. · 2017 - 2019Cross Sectional and Longitudinal Studies of Immune Complexes in SLE
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2018 - 2019External Relationships
- American College of Rheumatology
- Ampel Biosolutions
- AstraZeneca
- Aurinia Pharmaceuticals
- Biogen Idec Inc.
- Exagen
- Immunovant
- North Carolina Rheumatology Association
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.